TRACON Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration (wet AMD). The company's pipeline consists of product candidates such as TRC105, TRC102, TRC253, TRC694, and TRC205. The lead product TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or programmed cell death protein 1 pathway.
| Website: | www.traconpharma.com |
| Email: | Andrew@lifesciadvisors.com |
| Main Phone: | +1 858 550-0780 |
| Address: | 4350 La Jolla Village Drive |
| Address 2: | Suite 800 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92122 |
| Exchange: | NSD |
| CEO: | Charles P. Theuer |
| Employees: | 27 |
| NAICS: | Medicinal and Botanical Manufacturing(325411) |
Roth Conference company presentations begin this morning. We'll be watching 3 biotechs: TCON, CUR and ATNM.
Tracon Pharmaceuticals (TCON) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular
There are 11 new IPOs set to debut this week in the market. While it's not the biggest IPO on the list, burger chain Shake Shack (SHAK) is one name investors will be watching. Full IPO
Existing Home Sales fell 0.9% in February to an annual rate of 4.59 million homes, weaker than expectations. The Dow Jones Industrial Average traded between 13,158.11 and 13,190.02 in the opening
Gathering Data... Please wait TRACON Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration (wet AMD). The company's pipeline consists of product candidates such as TRC105, TRC102, TRC253, TRC694, and TRC205. The lead product TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or programmed cell death protein 1 pathway.
| Website: | www.traconpharma.com |
| Email: | Andrew@lifesciadvisors.com |
| Main Phone: | +1 858 550-0780 |
| Address: | 4350 La Jolla Village Drive |
| Address 2: | Suite 800 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92122 |
| Exchange: | NSD |
| CEO: | Charles P. Theuer |
| Employees: | 27 |
| NAICS: | Medicinal and Botanical Manufacturing(325411) |
Roth Conference company presentations begin this morning. We'll be watching 3 biotechs: TCON, CUR and ATNM.
Tracon Pharmaceuticals (TCON) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular
There are 11 new IPOs set to debut this week in the market. While it's not the biggest IPO on the list, burger chain Shake Shack (SHAK) is one name investors will be watching. Full IPO
Existing Home Sales fell 0.9% in February to an annual rate of 4.59 million homes, weaker than expectations. The Dow Jones Industrial Average traded between 13,158.11 and 13,190.02 in the opening
| Last Price 0.35 | Change $ 0.0273 | Change % 8.43 | Tick N/A |
| Bid 0.35 | Bid Size 12,800.00 | Ask 0.36 | Ask Size 500.00 |
| Open 0.33 | High 0.37 | Low 0.31 | Prev Close 0.32 |
| Last Trade | Volume 1.1 mi | 52 Wk Hi 1.73 | 52 Wk Low 0.29 |
| Market Cap 10.5 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 29,937,457.00 | EPS (TTM) -1.00 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 18 | 21 |
| Number of Buys | 18 | 18 |
| Number of Sells | 0 | 3 |
| Net Activity | 12743352 | 12727428 |
| Last 10 Buys | Shares |
|---|---|
| Peter Sonsini | 1,000 |
| Peter Sonsini | 1,000 |
| Ravi Viswanathan | 1,000 |
| Ravi Viswanathan | 1,000 |
| David M. Mott | 1,000 |
| David M. Mott | 1,000 |
| Sandell D Scott | 1,000 |
| Sandell D Scott | 1,000 |
| Anthony A. Florence | 1,000 |
| Anthony A. Florence | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| William R. Larue | 1,000 |
| Ronald L. Shazer | 1,000 |
| Charles P. Theuer | 1,000 |
| H Casey Logan | 1,000 |
| Charles P. Theuer | 1,000 |
| Charles P. Theuer | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 6 | 6 | 6 | 6 |
| Low Target Price Estimate | 5.5 | 5.5 | 5.5 | 5.5 |
| Mean Target Price Estimate | 5.75 | 5.75 | 5.75 | 5.75 |
| Standard Deviation | 0.35 | 0.35 | 0.35 | 0.35 |
| Date of Most Recent Estimate | 05/15/18 | 05/15/18 | 05/15/18 | 05/15/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-13 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-30 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-30 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2 | 2 | 1.67 | 1.67 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
